Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

CEO to participate in ARVO SIG panel on oral medications for retinal diseases

ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42^nd Annual Scientific Meeting

Read more at globenewswire.com